Skip to main content
SpringerLink
Log in

Dutasteride “cost-effective” for BPH in Poland

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Kaczor M, Pawlik D, Becla L, Dardzinski W, Jasinska A, Wojcik R, Walczak J, Nogas G, Cel M, Glogowski C, Zespol-Instytutu A.Cost-effectiveness of dutasteride in the treatment of benign prostatic hyperplasia. Value in Health 9: A253-A254 (plus poster) abstr. PIH5, No. 6, Nov-Dec 2006

  2. Dardzinski W, Pawlik D, Walczak J, Wojcik R, Kaczor M, Nogas G, Glogowski C, Cel M.Budge impact analysis of Avodart (dutasteride) in the treatment of benign prostatic hyperplasia in Poland. Value in Health 9: A252 (plus poster) abstr. PIH1, No. 6, Nov-Dec 2006

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dutasteride “cost-effective” for BPH in Poland. Pharmacoecon. Outcomes News 517, 5 (2006). https://doi.org/10.2165/00151234-200605170-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200605170-00008

Keywords

Search

Navigation